Oncology

The Pharmacy Times® Oncology resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

What can we help you find?

FDA Approves Acalabrutinib for CLL Indication

Under a new international collaboration, the FDA has granted supplemental approval to acalabrutinib (Calquence, AstraZeneca) for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic leukemia.

Triple Combo Therapy Shows Potential as First-line Treatment in Stage 4 NSCLC

Durvalumab (Imfinzi, AstraZeneca) and tremelimumab plus chemotherapy improved progression-free survival in first-line stage 4 non-small cell lung cancer.

Study: Affordable Care Act Improved Insurance Coverage for People With Both Cancer, HIV

A recent study published in CANCER indicates that for patients with both HIV and cancer, implementation of the Patient Protection and Affordable Care Act (ACA) improved insurance coverage, both in states that expanded Medicaid coverage and in states that did not.¹

Weight Loss Surgery Associated with Breast Cancer Risk Reduction

Weight loss surgery found to cut the overall risk of developing cancers linked to obesity by 20%.

Nivolumab-Ipilimumab Combo Receives FDA Breakthrough Designation for Advanced Hepatocellular Carcinoma

FDA breakthrough designation is based on data for nivolumab plus ipilimumab in a study evaluating the immuno-oncology combination in patients with advanced hepatocellular carcinoma previously treated with sorafenib.

First Rituximab Biosimilar Now Available in the US for Non-Hodgkin Lymphoma, CLL

Rituximab-abbs (Truxima, Teva and Celltrion), has been launched in the United States with a full oncology label for non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Sandoz Receives FDA Approval for Pegfilgrastim Biosimilar

Pegfilgrastim-bmez (Ziextenzo, Sandoz), a biosimilar to pegfilgrastim (Neulasta), is indicated to decrease the incidence of febrile neutropenia, a serious adverse effect of chemotherapy.

Practice Pearl 4: Future Implications of Subcutaneous Dosing

Concluding the discussion, the panel considers future directions for subcutaneous dosing.

Observation After Surgery as Efficacious as Radiotherapy in Men with Prostate Cancer

The largest ever trial of postoperative radiotherapy in prostate cancer shows men may be spared the procedure after surgery.

Top news of the day from across the health care landscape

High-Dose Radiation Effective in Men with Oligometastatic Prostate Cancer

Men treated with stereotactic ablative radiotherapy found to live significantly longer without any detectable disease progression compared with patients who received no additional treatment.

Single-Cell Level Variability May Help Predict Responses to BRAF Inhibitors in Melanoma

A study assessing melanoma cell variability indicates that identifying differences in cell states can be leveraged to improve patient outcomes.

The Pharmacy Times® Hematology specialty page serves as a hub for all clinical news and articles related to hematological conditions. The coverage includes updates from the floor of all the biggest societal conferences and annual meetings, like the American Society of Hematology Annual Meeting, as well as video interviews of the leading hematologists and key opinion leaders in the space.